Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eradication of Helicobacter pylori: clarithromycin-based vs levofloxacin-based quadruple therapy
IRCT20171223038001N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of clarithromycin and levofloxacin in Helicobacter pylori infection (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Helicobacter pylori eradication rate. Started Dec 2017; status: completed.
02
Drugs
clarithromycinlevofloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20171223038001N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171223038001N1.